Pharmacy Bulletin

Pharmacy Bulletin

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

VativoRx Bottle update

Kloxxado™ (naloxone) – New drug approval

The FDA announced the approval of Hikma Pharmaceuticals’ Kloxxado (naloxone), for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients. April 30, 2021

Absorica® (isotretinoin) – First-time generic

Teva launched an AB-rated generic version of Sun’s Absorica (isotretinoin) capsules. April 30, 2021

Farxiga® (dapagliflozin) – New indication

The FDA announced the approval of AstraZeneca’s Farxiga (dapagliflozin), to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease (CKD) at risk of progression. April 30, 2021

Ferriprox® (deferiprone) – New indication, expanded indication

Chiesi Global Rare Diseases announced the FDA approval of Ferriprox (deferiprone), for the treatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with sickle cell disease or other anemias. May 1, 2021

Natroba® (spinosad) – New indication

The FDA approved ParaPRO’s Natroba (spinosad), for the topical treatment of scabies infestations in adult and pediatric patients 4 years of age and older. April 28, 2021

This information is shared with you from our partners at OptumRx.

If you’d like to receive the weekly bulletin by email, please let us know.